ArticleDiscover oncology2026
Progranulin promotes glioma progression via interaction with cathepsin D and serves as a diagnostic and prognostic biomarker.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Progranulin (PGRN) plays a crucial role in the progression of various tumor types, making it a potentially valuable biomarker. However, the roles of PGRN vary across tumor types. Therefore, this study aimed to comprehensively analyze PGRN expression in different tumor types to better understand and apply biomarker-guided cancer therapy. The pan-cancer data were obtained from the University of California Santa Cruz Xena platform, and PGRN expression was extensively examined across various cancer types and the corresponding normal tissues. R packages were used for data analysis, including survival outcomes, baseline characteristic assessments, and univariate and multivariate Cox regression models to evaluate the prognostic significance of PGRN. Quantitative real-time polymerase chain reaction (qPCR), co-immunoprecipitation assay, and immunoblotting were performed for molecular interaction and expression. Real-time cell analysis and migration and invasion assays were conducted for phenotype examination. Results showed that PGRN promotes glioma cell proliferation, migration, and invasion. It also interacts with precursor cathepsin D (CTSD) and facilitates its maturation, thereby linking PGRN's tumor-promoting effects to CTSD. PGRN can be used as a diagnostic and prognostic biomarker for gliomas. Our study offers a foundational framework for using PGRN in glioma diagnosis and prognosis. The potential of PGRN as both a diagnostic and prognostic biomarker was identified suggesting novel avenues for targeted therapeutic strategies in glioma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.